Biotechnology
iOrganBio Appoints AI and Life Sciences Investor Jessica Owens to Board of Directors
iOrganBio has appointed Jessica Owens, a seasoned venture investor and co-founder of GRAIL, to its board to help scale its AI-driven cell manufacturing platform.
KALA BIO Implements 1-for-50 Reverse Stock Split, Reducing Outstanding Shares from 929.5 Million to 18.6 Million
KALA BIO executed a 1-for-50 reverse stock split to meet Nasdaq listing requirements and consolidate its capital structure, effective May 11, 2026.
Pipeline Maturity Reshapes Biotech Valuations as Clinical Progress Gains Weight
The biotechnology industry's valuation model is shifting from a revenue-centric approach to one that prioritizes clinical-stage progression and probability of success, with companies like Oncotelic Therapeutics exemplifying this trend.
Lantern Pharma Unveils Multi-Agent AI and Computational Biology Tools for withZeta.ai Platform
Lantern Pharma announced the next phase of its withZeta.ai platform, including ZetaSwarm and ZetaOmics, which could accelerate oncology research and create a new revenue stream for the company.
Oragenics Signs LOI to License CardioDialysis Technology for Brain Disorders
Oragenics Inc. has signed a letter of intent to license Sigyn Therapeutics' CardioDialysis blood purification technology, aiming to combine it with its intranasal neurosteroid candidate ONP-002 for a dual-modality approach to traumatic brain injury and neurodegenerative diseases.
Oncotelic Therapeutics Completes $12.5M Asset Transfer to Lunai Bioworks, Focusing on Nose-to-Brain Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics has transferred worldwide rights to its nose-to-brain delivery system for Alzheimer's and biodefense to Lunai Bioworks in exchange for $12.5 million in preferred stock, enabling it to monetize assets while retaining control for other indications like Parkinson's disease.
MilliporeSigma Expands Temecula Biotech Hub, Advancing Organoid Research and Personalized Medicine
MilliporeSigma's investments in Temecula, including a new organoid lab and acquisition of HUB Organoids, position the site at the forefront of disease modeling and personalized medicine, while reinforcing its community commitment.
Cardio Diagnostics Leverages AI and Biomarkers to Combat Cardiovascular Disease
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is advancing early detection of heart disease using a platform that combines artificial intelligence with multi-omic biomarker analysis, addressing the urgent need for innovation in cardiovascular care.
BioStem Technologies to Report First Quarter 2026 Results on May 14
BioStem Technologies will release Q1 2026 financial results on May 14, 2026, followed by a conference call and webcast at 4:30 PM ET, offering investors insight into the company's performance and growth trajectory in regenerative medicine.
BioStem Appoints Katherine Gorrell as Chief Legal & Compliance Officer, Signaling Growth and Nasdaq Uplisting Ambitions
BioStem Technologies strengthens its leadership by appointing Katherine Gorrell, a seasoned legal and compliance executive, to oversee governance and regulatory strategy as the company pursues a Nasdaq uplisting.
VolitionRx Achieves Technical Milestone in Sepsis Detection with Finger-Prick Prototype
VolitionRx announced a prototype that can detect nucleosomes in capillary blood from sepsis patients, potentially enabling point-of-care testing and expanding access in regions with limited lab infrastructure.
GeoVax Advances Gedeptin Toward Phase 2 Initiation and Strategic Partnership Opportunities
GeoVax Labs outlines near-term milestones for its oncology candidate Gedeptin, including a planned Phase 2 trial in head and neck cancer, as it seeks combination therapy partnerships.
Lexaria Bioscience Extends Material Transfer Agreement with PharmaCO Through 2026
Lexaria Bioscience has extended its Material Transfer Agreement with an undisclosed pharmaceutical company to evaluate its DehydraTECH technology for GLP-1 drugs, allowing for continued collaboration and review of upcoming R&D results.
LakeShore Biopharma Amends Merger Agreement, Slashes Share Consideration to $0.066 in Going-Private Deal
LakeShore Biopharma has amended its merger agreement to take the company private at a reduced equity value of $2.7 million, offering $0.066 per share after a revised proposal from the buyer group.
BioAdaptives Launches MyndMed Cognitive-Support Supplement After Positive Testing
BioAdaptives Inc. announced the commercial launch of MyndMed, a dietary supplement for cognitive support, following successful testing and strong early demand, with production scaling and distribution expanding nationwide.
LIXTE Biotechnology Advances Precision Oncology with Novel PP2A Inhibitor LB-100
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor that enhances chemotherapy and immunotherapy while reducing side effects, with ongoing clinical trials for ovarian and colon cancers.
TransCode Therapeutics Appoints Scientific Advisory Board Chair, Partners with Michigan State University to Advance RNA-Based Cancer Therapies
TransCode Therapeutics announced the appointment of Dr. Anna Moore as Chair of its Scientific Advisory Board and a sponsored research agreement with Michigan State University to advance its RNA-based therapeutic pipeline, including lead candidate TTX-MC138.
LIXTE Biotechnology Advances Precision Cancer Treatment with Novel PP2A Inhibitor
LIXTE Biotechnology is pioneering a new approach in oncology with its lead compound LB-100, which enhances chemotherapy and radiation efficacy while reducing side effects, potentially improving patient outcomes.
Scinai Immunotherapeutics Raises $2.61M to Expand CDMO Platform and Advance Pipeline
Scinai Immunotherapeutics announced a $2.61 million private placement and warrant inducement, with proceeds supporting its CDMO expansion and immunotherapy pipeline.
Oncotelic Therapeutics Featured in NetworkNewsAudio Editorial Highlighting How Late-Stage Drug Pipelines Drive Valuation in Biotech
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is featured in a NetworkNewsAudio editorial that explores how advancing drug pipelines, particularly those near commercialization, create significant value in biopharma, directly relevant to Oncotelic's oncology-focused pipeline.
Oncotelic Therapeutics Highlights Partnership Strategy to Advance Pipeline and Boost Shareholder Value
Oncotelic Therapeutics updates its partnership-driven strategy, citing a $249 million valuation boost from its GMP Biotechnology joint venture and plans for further collaborations to advance its oncology pipeline efficiently.
Soligenix's Platform Approach to Drug Development Offers Efficiency in Biopharmaceutical Innovation
Soligenix Inc. demonstrates how platform-based drug development using synthetic hypericin across multiple dermatologic conditions can streamline clinical impact and reduce redundancy in the biotech industry.
MindBio Therapeutics Engages Market-Making Services to Enhance Stock Liquidity
MindBio Therapeutics has appointed Venture Liquidity Providers to maintain orderly trading for its shares, signaling confidence in its AI voice analytics technology for intoxication detection.
Polyrizon Secures $3.5 Million in Funding to Advance Intranasal Protective Technology
Polyrizon Ltd. has raised $3.5 million through a registered direct offering and private placement to fund development of its nasal spray hydrogel technology designed to create protective barriers against viruses and allergens.
Kairos Pharma Recognized for Innovation in Overcoming Cancer Drug Resistance
Kairos Pharma Ltd. has been honored with the 2026 Pinnacle Award for its pioneering work on resistance-modulating treatments that aim to enhance the effectiveness of existing cancer therapies.
Analytical Validation Strengthens Soligenix Outlook as Pipeline Advances
A recent Zacks Small-Cap Research report highlights Soligenix's clinical progress and upcoming milestones, particularly in its phase 3 FLASH2 trial for cutaneous T-cell lymphoma treatment, reinforcing the company's strategic credibility and valuation potential.
Oncotelic Therapeutics Exemplifies Biotech Sector's Shift Toward Pipeline-Driven Valuation
Oncotelic Therapeutics illustrates how biotechnology companies are increasingly being valued based on clinical progress and pipeline assets rather than traditional metrics, representing a fundamental shift in sector valuation practices.
Personalized mRNA Vaccine Shows Promise in Extending Pancreatic Cancer Survival
A personalized mRNA vaccine has demonstrated potential to meaningfully extend survival for pancreatic cancer patients, according to six-year trial results presented at a major oncology conference.
Biotech Valuations Shift as Scientific Progress Gains Financial Recognition
The biotechnology industry is undergoing a transformation where scientific advancement is increasingly quantified as financial assets through fair-value accounting, with companies like Oncotelic Therapeutics demonstrating how clinical progress translates to tangible economic value.
Oncotelic Therapeutics Reports $249 Million Net Income for FY 2025 Driven by Joint Venture Valuation
Oncotelic Therapeutics announced a dramatic financial turnaround with $249 million net income for fiscal year 2025, primarily due to a non-cash gain from its GMP Biotechnology joint venture valuation, signaling potential growth in its oncology and COVID-19 drug pipeline.